Background: With the integration of various targeted therapies into the clinical management
of patients with advanced lung adenocarcinoma, next-generation sequencing (NGS) has …

Identification of targetable molecular changes is essential for selecting appropriate treatment
in patients with advanced lung adenocarcinoma. Methods: In this study, a Sanger …

Background: Next-generation sequencing (NGS) has been widely applied in clinical
research, while its application in routine clinical molecular testing requires careful validation …

Objectives Molecular diagnosis determines therapeutic strategies for patients with non-small-
cell lung cancer–adenocarcinoma (NSCLC-A) but depends on resources availability. We …

Background In a significant percentage of advanced non-small cell lung cancer (NSCLC)
patients, tumor tissue is unavailable or insufficient for genetic analyses at time to …

Identification of multi-gene variations has led to the development of new targeted therapies
in lung adenocarcinoma patients and identification of an appropriate patient population with …

9085 Background: The Network Genomic Medicine (NGM) Lung Cancer is a health care
provider network offering comprehensive next generation sequencing (NGS)-based …

Despite the widespread application of next-generation sequencing (NGS) in advanced lung
adenocarcinoma, its impact on survival and the optimal timing for the examination remain …

Lung cancer is biologically aggressive and is the leading cause of cancer-related deaths.
The development of lung cancer is unique in each patient according to clinical …

Introduction Targeted therapy significantly prolongs survival in lung adenocarcinoma.
Current diagnostic guidelines include only EGFR and anaplastic lymphoma receptor …